Stock PANACEABIO PANACEA BIOTEC LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Panacea Biotec Limited Bombay S.E.

Equities

PANACEABIO

INE922B01023

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:50 2024-04-26 am EDT 		5-day change 1st Jan Change
144 INR -1.51% Intraday chart for Panacea Biotec Limited +5.42% -14.34%
Apr. 13 Panacea Biotec Limited Appoints Ambika Sharma as Non-Executive Independent Director CI
Apr. 01 Panacea Biotec Limited Announces the Cessation of Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narasimhan as Independent Directors CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 16,363 12,131 6,692 10,958 9,077 6,643
Enterprise Value (EV) 1 25,570 18,451 13,711 18,241 3,926 4,714
P/E ratio -22.1 x 32.2 x -3.44 x -7.42 x 0.84 x -20 x
Yield - - - - - -
Capitalization / Revenue 2.76 x 2.66 x 1.23 x 1.75 x 1.37 x 1.44 x
EV / Revenue 4.31 x 4.04 x 2.52 x 2.92 x 0.59 x 1.02 x
EV / EBITDA 26.8 x -33.1 x 15.9 x 20.9 x -62.4 x -7.35 x
EV / FCF 34.8 x -258 x -13.5 x 11.1 x 1.54 x -1.1 x
FCF Yield 2.88% -0.39% -7.4% 9.03% 64.9% -91.1%
Price to Book 5.3 x 3.56 x 3.78 x -4.38 x 1.1 x 0.81 x
Nbr of stocks (in thousands) 61,251 61,251 61,251 61,251 61,251 61,251
Reference price 2 267.2 198.0 109.2 178.9 148.2 108.4
Announcement Date 8/14/18 9/6/19 12/2/20 9/3/21 9/6/22 9/7/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 5,928 4,567 5,441 6,248 6,612 4,599
EBITDA 1 953 -558.1 861.2 872.6 -62.91 -641.2
EBIT 1 387.1 -1,098 429 427.3 -489.6 -1,027
Operating Margin 6.53% -24.04% 7.88% 6.84% -7.41% -22.34%
Earnings before Tax (EBT) 1 -661.4 486.2 -1,712 -1,442 14,488 128
Net income 1 -739.8 377.3 -1,943 -1,477 10,779 -332.4
Net margin -12.48% 8.26% -35.71% -23.64% 163.01% -7.23%
EPS 2 -12.08 6.159 -31.72 -24.11 176.0 -5.426
Free Cash Flow 1 735.6 -71.6 -1,015 1,648 2,548 -4,293
FCF margin 12.41% -1.57% -18.65% 26.38% 38.53% -93.34%
FCF Conversion (EBITDA) 77.18% - - 188.85% - -
FCF Conversion (Net income) - - - - 23.63% -
Dividend per Share - - - - - -
Announcement Date 8/14/18 9/6/19 12/2/20 9/3/21 9/6/22 9/7/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 9,207 6,320 7,020 7,283 - -
Net Cash position 1 - - - - 5,151 1,928
Leverage (Debt/EBITDA) 9.661 x -11.33 x 8.151 x 8.346 x - -
Free Cash Flow 1 736 -71.6 -1,015 1,648 2,548 -4,293
ROE (net income / shareholders' equity) -22.6% 12.5% -69.2% 814% 351% -3.94%
ROA (Net income/ Total Assets) 1.42% -4.6% 1.94% 2.08% -2.07% -4.24%
Assets 1 -52,105 -8,199 -100,205 -71,038 -521,297 7,842
Book Value Per Share 2 50.40 55.60 28.90 -40.90 135.0 134.0
Cash Flow per Share 2 2.680 2.360 6.570 8.500 8.220 6.510
Capex 1 152 47.8 69.1 218 125 409
Capex / Sales 2.57% 1.05% 1.27% 3.48% 1.89% 8.9%
Announcement Date 8/14/18 9/6/19 12/2/20 9/3/21 9/6/22 9/7/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PANACEABIO Stock
  4. PANACEABIO Stock
  5. Financials Panacea Biotec Limited